March 3, 2023 10:37 AM ESTUpdated 03:18 PM
Financing

Sang­amo scraps pub­lic of­fer­ing ‘af­ter eval­u­at­ing mar­ket con­di­tions’

Lei Lei Wu

News Reporter

Sang­amo Ther­a­peu­tics has with­drawn its pub­lic stock of­fer­ing, ac­cord­ing to an SEC fil­ing Fri­day morn­ing. The cell and gene ther­a­py biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times